Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 79.28% is 128% above its 5-year average of -283.50%, near the high end of its 5-year range (-9575.44%–100.00%).
14.13% below its 12-month average of 92.33%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
79.28%
GROSS MARGIN AVG TTM
92.33%
GROSS MARGIN AVG 3Y
93.69%
GROSS MARGIN AVG 5Y
-283.50%
GROSS MARGIN AVG 10Y
-864.47%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-14.13%
CURRENT VS 3Y AVG
-15.38%
CURRENT VS 5Y AVG
+127.96%
CURRENT VS 10Y AVG
+109.17%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+91.59%
vs the sector median at left
Wave Life Sciences Ltd.
Market Cap
$693.61M
Gross Margin
79.28%
TTM Avg
92.33%
3Y Avg
93.69%
5Y Avg
-283.50%
Market Cap
$693.19M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$694.79M
Gross Margin
53.23%
TTM Avg
53.64%
3Y Avg
56.38%
5Y Avg
57.18%
Market Cap
$691.79M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$685.49M
Gross Margin
-16.57%
TTM Avg
15.14%
3Y Avg
17.91%
5Y Avg
27.64%
Market Cap
$702.82M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$681.27M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
33.33%
Market Cap
$709.65M
Gross Margin
60.02%
TTM Avg
59.55%
3Y Avg
55.45%
5Y Avg
55.70%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Wave Life Sciences Ltd. (WVE) | $693.61M | 79.28% | 92.33% | 93.69% | -283.50% |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.19M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cytek Biosciences, Inc. (CTKB)vs › | $694.79M | 53.23% | 53.64% | 56.38% | 57.18% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $691.79M | 0.00% | 0.00% | 0.00% | 0.00% |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | -16.57% | 15.14% | 17.91% | 27.64% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $702.82M | 0.00% | 0.00% | 0.00% | 0.00% |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | 0.00% | 0.00% | 25.00% | 33.33% |
| Verastem, Inc. (VSTM)vs › | $681.02M | 86.69% | 91.43% | 70.72% | 74.12% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | 60.02% | 59.55% | 55.45% | 55.70% |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 78.85% | 82.67% | 82.58% | 83.02% |
Gross Margin
79.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 100.00% |
| 2025-12-31 | 86.88% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 74.76% |
| 2025-03-31 | 76.41% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 92.49% |
| 2023-09-30 | 35.71% |
| 2023-06-30 | -50.70% |
| 2023-03-31 | -139.61% |
| 2022-12-31 | -2408.31% |
| 2022-09-30 | -9575.44% |
| 2022-06-30 | -7828.80% |
| 2022-03-31 | -1469.71% |
| 2021-12-31 | -1359.55% |
| 2021-09-30 | 14.65% |
| 2021-06-30 | -1039.59% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | -218.18% |
| 2020-09-30 | -719.57% |
| 2020-06-30 | -939.91% |
| 2020-03-31 | -889.14% |
| 2019-12-31 | -1947.00% |
| 2019-09-30 | -1422.19% |
| 2019-06-30 | -445.42% |
| 2019-03-31 | -1225.61% |
| 2018-12-31 | -999.70% |
| 2018-09-30 | -631.72% |
| 2018-06-30 | -567.08% |
| 2018-03-31 | -1953.16% |
| 2017-12-31 | -1413.66% |
| 2017-09-30 | -2872.93% |
| 2017-06-30 | -2725.89% |
| 2017-03-31 | -2080.47% |
| 2016-12-31 | -1970.27% |
| 2016-09-30 | -3391.33% |
| 2016-06-30 | -1914.63% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | -2181.58% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | -1368.25% |
| 2015-03-31 | -6080.77% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
